On the other hand, the presence of MGMT promoter hypermethylation in a percentage of MEN1 NF-pNETs could increase their sensitivity and responsiveness to treatment with temozolomide and other alkylating agents; evaluation of methylation status of the MGMT promoter in tumor biopsies may serve as a predictive pharmacoepigenetic biomarker of response to chemotherapeutic alkylating molecules in MEN1 patients with advanced NF-pNETs. The gene discussed is MEN1; the disease is neoplasm.